Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| Weiss Ratings | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.10 | |||
| Price History | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 38.89% | |||
| 60-Day Total Return | -56.14% | |||
| 90-Day Total Return | -53.87% | |||
| Year to Date Total Return | -52.83% | |||
| 1-Year Total Return | -24.70% | |||
| 2-Year Total Return | -3.85% | |||
| 3-Year Total Return | -73.03% | |||
| 5-Year Total Return | -81.03% | |||
| 52-Week High % Change | -64.77% | |||
| 52-Week Low % Change | 140.08% | |||
| Price | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.54 | |||
| 52-Week Low Price | $0.52 | |||
| 52-Week Low Price (Date) | Jan 10, 2025 | |||
| 52-Week High Price (Date) | Nov 07, 2024 | |||
| Valuation | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.49M | |||
| Enterprise Value | 57.09M | |||
| Price/Earnings (TTM) | 1.17 | |||
| Earnings Per Share (TTM) | 1.07 | |||
| Earnings Per Share Growth | -374.68% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.12 | |||
| Price/Book (Q) | -0.10 | |||
| Enterprise Value/Revenue (TTM) | 1.27 | |||
| Price | $1.25 | |||
| Enterprise Value/EBITDA (TTM) | 8.61 | |||
| Enterprise Value/EBIT | 8.98 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 4.42M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 855 776 6419 | |||
| Address | Waterview Plaza Parsippany, NJ 07054 | |||
| Website | www.interpace.com | |||
| Country | United States | |||
| Year Founded | 1986 | |||
| Profitability | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 14.15% | |||
| Profit Margin | 10.46% | |||
| Management Effectiveness | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 28.09% | |||
| Return on Equity | -- | |||
| Income Statement | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 44.89M | |||
| Total Revenue (TTM) | 44.89M | |||
| Revenue Per Share | $10.15 | |||
| Gross Profit (TTM) | 27.14M | |||
| EBITDA (TTM) | 6.63M | |||
| EBIT (TTM) | 6.36M | |||
| Net Income (TTM) | 4.70M | |||
| Net Income Avl. to Common (TTM) | 4.70M | |||
| Total Revenue Growth (Q YOY) | 35.44% | |||
| Earnings Growth (Q YOY) | 357.95% | |||
| EPS Diluted (TTM) | 1.07 | |||
| EPS Diluted Growth (Q YOY) | 304.99% | |||
| Balance Sheet | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.11M | |||
| Cash Per Share (Q) | $0.48 | |||
| Total Current Assets (Q) | 11.11M | |||
| Total Preferred Equity (Q) | 46.54 | |||
| Total Equity (Q) | -11.15M | |||
| Current Ratio (Q) | 0.592 | |||
| Book Value Per Share (Q) | -$13.10 | |||
| Total Assets (Q) | 14.04M | |||
| Total Current Liabilities (Q) | 18.77M | |||
| Total Debt (Q) | 7.18M | |||
| Total Liabilities (Q) | 25.19M | |||
| Total Common Equity (Q) | -57.68M | |||
| Cash Flow | IDXG - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -889.00K | |||
| Cash from Financing (TTM) | -6.63M | |||
| Net Change in Cash (TTM) | -2.92M | |||
| Levered Free Cash Flow (TTM) | 2.40M | |||
| Cash from Operations (TTM) | 4.60M | |||
